logo
TYLENOL® Expands Expertise to Proactive Joint Care with Launch into the Supplement Category

TYLENOL® Expands Expertise to Proactive Joint Care with Launch into the Supplement Category

From relief to routine: Proactive Support from the Makers of TYLENOL® delivers clinically backed ingredients that provide effective, drug-free joint support.†
SUMMIT, N.J., June 2, 2025 /PRNewswire/ -- The Makers of TYLENOL® have announced the launch of Proactive Support, a drug-free supplement designed to support joint comfort and mobility.†
The innovation is powered by a proprietary TamaFlex® blend of turmeric and tamarind that is clinically shown to improve joint comfort, flexibility and function – in as early as five days.† Its mechanism of action supports the body's healthy inflammatory response to your active lifestyle and improves mobility.†
Leveraging decades of science-backed expertise, Proactive Support from TYLENOL® was developed with feedback from healthcare professionals to meet a consumer need for drug-free joint support. A recent study* suggests the human aging process accelerates around the age of 44 and at age 60 – a time when it's critical to focus on healthy, proactive habits to support joint health, which can be impacted by everyday aging, activity or stressors. Now, consumers can experience improved joint comfort and mobility† with one pill – no need for multiple large pills or complicated routines.
'As the #1 selling pain relief brand in the U.S. with more than 60 years of experience, we are proud to use our heritage to offer science-backed, proactive options to improve joint health† and further our mission to Care Without Limits™,' said Jen Gow, Head of U.S. Pain at Kenvue. 'This launch expands the TYLENOL® brand into the supplement space and provides consumers an offering to build a more complete toolkit for wellness.'
New Proactive Support from TYLENOL® comes in two patent-pending formulas – Muscle & Joint and Muscle & Joint + Stress – neither of which contain acetaminophen. Both options include a proprietary TamaFlex® blend of turmeric and tamarind. Consumers can choose the option right for them based on their needs.
'This collaboration with the Makers of TYLENOL® marks an exciting milestone for TamaFlex® and for consumers looking for efficacious joint support options that can be used daily,' said Eric Anderson, Managing Director of NXT USA. 'Thanks to the strength of clinically supported ingredients found in Proactive Support, users can experience improved joint comfort and mobility.†"
To champion the launch of Proactive Support, TYLENOL® is collaborating with a roster of trusted partners, including beloved actor Molly Shannon, known for her physical comedy and whose authentic approach to staying active reflects the product's mission. Across social media, lifestyle creators will share how they are adding Proactive Support from TYLENOL® to their regimens, while experts Tatiana Lampa, Corrective Exercise Specialist, and Kathleen Benson, RDN, will recommend holistic ways for consumers to support their joint health through movement and nutrition.
'I often recommend that my clients add ingredients like turmeric that have been associated with potential health benefits to their diets – and the ingredient blend in Proactive Support from TYLENOL® is clinically shown to help the body support healthy joints†,' said Kathleen Benson, TYLENOL® RD Partner. 'By stretching, taking a daily Proactive Support supplement and following a strength training routine, consumers can take an active role in managing joint comfort and flexibility.†"
The Proactive Support launch will span TV, digital, social and retail media. Consumers can find Proactive Support where they find TYLENOL® at major retailers including Amazon, Walmart and CVS. The manufacturer's suggested retail price is $19.99.
* 2024 Study Stanford Data Science Initiative
†These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
About TYLENOL®
TYLENOL® – the #1 doctor-recommended brand of pain and fever relief – offers a growing portfolio of products designed to help people manage their health. From trusted OTC medicines to innovative topicals and daily supplements, TYLENOL® is committed to providing Care Without Limits™ by addressing a wide range of needs across ages and through every stage of life.
About Kenvue
Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson's®, Listerine®, Neutrogena®, and TYLENOL®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.
Contact:
Samantha Higgins
Communications Lead, TYLENOL®
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/tylenol-expands-expertise-to-proactive-joint-care-with-launch-into-the-supplement-category-302469852.html
SOURCE Kenvue Inc.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

Yahoo

time32 minutes ago

  • Yahoo

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base. The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa. " This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica's TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients. ," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica signs agreement with fifth Tier-1 US biopharma company SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio

MMA INNOVATE VIETNAM 2025: Important Marketing Event for Vietnam Martech Ecosystem
MMA INNOVATE VIETNAM 2025: Important Marketing Event for Vietnam Martech Ecosystem

Yahoo

time32 minutes ago

  • Yahoo

MMA INNOVATE VIETNAM 2025: Important Marketing Event for Vietnam Martech Ecosystem

HO CHI MINH CITY, Vietnam, June 11, 2025 /PRNewswire/ -- MMA INNOVATE VIETNAM, the country's pioneering platform shaping the future of marketing, is back on 21 August 2025 — bigger, bolder, and brimming with opportunities to connect, collaborate, and co-create the next wave of digital transformation. The Vietnam MarTech Report 2024 shows just how quickly the space is evolving: the number of MarTech companies has skyrocketed from 15–20 players in 2023 to nearly 100 in 2024. Furthermore, the KPMG 2024 Customer Experience Excellence Report which highlights how Vietnamese businesses are already leveraging AI to elevate trust, security, and emotional connection — and you've got the perfect storm for innovation. Thus, INNOVATE 2025's theme, "Shaping Growth Through Marketing Insight, Impact, and Innovation," is more than a slogan. It's a call to action for top brands, ambitious SMEs, startups, and marketers to come together and thrive in the age of AI, MarTech, and experience-driven landscape of AI, MarTech, and customer experience. Impressive Numbers from MMA INNOVATE VIETNAM 2024 2,500+ delegates from all corners of the marketing industry Over 30 exhibition booths featuring major names like Samsung, Heineken, Coca-Cola, Nestlé, Unilever, Suntory PepsiCo, AIA, AdFlex, Ecomobi, Haravan, AnyMind, MGID, VCCorp, VietGuys, Chicilon Media, Novaon, Ureka Media, Appier, and many more. 62 speakers from multi-nation corps delivering global insights 25,000+ live views via MMA's social channels and media partners 20 million+ total reach across online and offline platforms Over 300 B2B connections made directly at the event. "MMA INNOVATE VIETNAM 2025 is not just an event – it's a launchpad for businesses to thrive. We believe AI and MarTech are the keys to creating meaningful differentiation for sustainable growth. MMA Global Vietnam is committed to supporting the business community, helping them seize opportunities, overcome challenges, and accelerate in the digital era." – Ms. Phan Bich Tam, Country Director, MMA Global Vietnam. Who Should Exhibit? Businesses and startups in marketing, MarTech, advertising, media, data, AI, and e-commerce. Providers of digital transformation solutions, technology platforms, and creative services. Brands looking to launch new products/services and seeking strategic partners. Book Your Booth Don't miss the chance to connect and grow your business at MMA INNOVATE VIETNAM 2025! Contact the organizing team via email: 0937 811 381Limited booths available – Book early to secure the best spots! PR Newswire is the official Media Partner of the MMA INNOVATE VIETNAM 2025. View original content to download multimedia: SOURCE MMA Vietnam Sign in to access your portfolio

Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025
Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025

Yahoo

timean hour ago

  • Yahoo

Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025

TAIPEI, June 11, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking place June 16–19 in Boston, MA. The company will be located at Booth #1645 within the Taiwan Pavilion, to showcase its innovative ENERGI Platform and provide a key update on its investigational Parkinson's disease (PD) therapy, ENERGI-F705PD, a first-in-class treatment with disease-modifying potential. Key Highlights: ENERGI-F705PD is a first-in-class, oral sustained-release therapy in development for Parkinson's disease, designed to address the underlying pathogenesis. Topline data from the Phase I trial in healthy subjects are anticipated in September 2025, following successful completion of recruitment. ENERGI-F705PD aims to combat the root causes of Parkinson's by reducing alpha-synuclein aggregation, enhancing antioxidant capacity, and boosting dopamine synthesis. "We are eager to present the exciting progress of our ENERGI-F705PD program at BIO International 2025," said Dr. Han-Min Chen, CEO of Energenesis Biomedical. "Parkinson's disease remains a challenging condition with significant unmet needs. Our approach focuses on restoring cellular energy and combating critical pathogenesis of PD, offering a potential disease-modifying solution for patients. We look forward to sharing our latest data and exploring potential partnerships that can accelerate the development of this important therapy." About ENERGI-F705PD ENERGI-F705PD is a novel small-molecule drug delivered in an oral sustained-release formulation. It is designed to enhance cellular ATP and antioxidant production by engaging the purine salvage, glycolysis, and pentose phosphate pathways. This multi-pronged mechanism of action directly addresses key pathological hallmarks of Parkinson's disease: Reduce and Prevent α-Synuclein Aggregation: Elevated ATP acts as a hydrotrope, helping prevent the intracellular aggregation of misfolded α-synuclein, a central pathogenic hallmark of PD. Increase Reducing Power (antioxidant): ENERGI-F705PD upregulates the pentose phosphate pathway (PPP), leading to increased NADPH production and enhanced cellular antioxidant defense. Increase Tyrosine Hydroxylase Expression/activity: By optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD also enhances the expression and activity of tyrosine hydroxylase (TH), the key enzyme in dopamine synthesis, thereby helping restore neurotransmitter levels in the brains of PD patients. About Energenesis Biomedical Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that restore cellular energy and activate intrinsic repair mechanisms. By combining proprietary small-molecule innovation with AI-driven drug repurposing, Energenesis Biomedical aims to accelerate the development of treatments for unmet medical needs across various therapeutic areas, including neurodegenerative diseases, chronic wounds, and rare disorders. The company's robust pipeline includes: ENERGI-F705PD: Oral tablet for Parkinson's disease (Phase I) ENERGI-F703DFU: Gel for Diabetic foot ulcers (Phase III) ENERGI-F701: Tonic for Alopecia (Phase II completed) ENERGI-F703EB: Cream for Epidermolysis bullosa (EB), granted FDA Orphan Drug and Rare Pediatric Disease designation, and EMA orphan designation(Preparing for Phase II) For more information, please visit Contact: Business Development Team Email: partnership@ View original content: SOURCE ENERGENESIS BIOMEDICAL CO., LTD. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store